Efficacy of galcanezumab in proline-rich transmembrane protein 2 (PRRT2)-associated familial hemiplegic migraine: A case series

Costanza Sottani, Giulia Di Lazzaro, Paolo Calabresi, Maria Grazia Pomponi, Francesco Danilo Tiziano, Anna Rita Bentivoglio, Serenella Servidei, Catello Vollono

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: Familial hemiplegic migraine (FHM) is a rare subtype of migraine with aura. Variants in calcium voltage-gated channel subunit alpha1 A (CACNA1A), ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2), and sodium voltage-gated channel alpha subunit 1 (SCN1A) genes have a well-established association with the development of FHM. Recent studies suggest that other genes may also have a significant role in the pathogenesis of FHM, including proline-rich transmembrane protein 2 (PRRT2). To our knowledge, there are currently no documented reports of the use of monoclonal antibodies targeting calcitonin gene-related peptide in FHM caused by a specific identified genetic mutation – and in particular not in FHM associated with PRRT2 mutations. The aim of our work is to describe the efficacy of galcanezumab as a prophylaxis treatment on patients from an Italian family consisting of six patient carriers of a PRRT2 pathogenic variant. Methods: Inclusion criteria for treatment eligibility consisted of a confirmed diagnosis of genetically confirmed FHM as defined by the International Classification of Headache Disorders, third edition, number of headache days/month ≥4, and at least two previously failed migraine prophylaxis treatments. We evaluated clinical data of patients treated with galcanezumab regarding number of headache days/month, frequency of aura, disability caused by HM using the Migraine Disability Assessment (MIDAS), attack severity through a numerical rating scale (NRS), acute medications intake, and response to acute medications at baseline (t0) and after 3 (t1) and 6 (t2) months of treatment. Results: Three out of six family members met inclusion criteria for treatment with galcanezumab. The average number of headache days/month, acute medications, and MIDAS significantly decreased in all treated patients, as well as the average NRS score. Aura frequency reduced by ≥50% compared to the baseline in all three patients. No adverse events related to galcanezumab were reported. Conclusion: Galcanezumab is a valid and well-tolerated treatment option in PRRT2-associated FHM.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaHeadache
DOI
Stato di pubblicazionePubblicato - 2024

Keywords

  • calcitonin gene‐related peptide
  • galcanezumab
  • hemiplegic familial migraine
  • proline‐rich transmembrane protein 2

Fingerprint

Entra nei temi di ricerca di 'Efficacy of galcanezumab in proline-rich transmembrane protein 2 (PRRT2)-associated familial hemiplegic migraine: A case series'. Insieme formano una fingerprint unica.

Cita questo